Developer docs
API playgroundTry for free, no card

Search company profiles

CyberGene

Full company profile

uuid002a5h9

Namestring
CyberGene
Legal namestring
CyberGene AB
Websiteurl
cybergene.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

CyberGene AB is a Swedish molecular diagnostics company founded in 1995 and headquartered in Solna, Sweden. The company developed and marketed diagnostic products in two specialized clinical areas: aneuploidy testing (chromosomal abnormality detection used in prenatal and reproductive health contexts) and male infertility testing. Its products were positioned to medical diagnostic laboratories and healthcare providers requiring molecular diagnostics solutions in reproductive genetics. The company operated with a small team of 1-10 employees and was a wholly-owned subsidiary of the Level Bio AB Group for an extended period prior to its divestiture.

The company's business model centered on the development, manufacture, and sale of proprietary diagnostic kits/tests in niche reproductive health segments. Pricing was not publicly disclosed, and no direct revenue figure was reported; however, the 2026 transaction terms imply 2025 net revenue of approximately SEK 7.2 million (~USD 0.83 million), calculated from the disclosed 1.7x revenue acquisition multiple. CyberGene served a vertical customer base of healthcare providers and diagnostic laboratories, with a focused, use-case-driven segmentation approach.

In February 2026, Devyser Diagnostics AB announced an agreement to acquire 100% of CyberGene shares from Level Bio AB for approximately SEK 12.2 million (~USD 1.4 million) via a directed new share issue. The transaction received regulatory clearance from the Swedish Inspectorate of Strategic Products under the Foreign Direct Investments Act and closed on April 1, 2026. Post-acquisition, CyberGene's products are being integrated into Devyser's diagnostic portfolio, with the deal expected to strengthen Devyser's aneuploidy and male infertility offering and have a positive impact on gross profit and EBIT. CyberGene's prior funding history includes an early-stage investment from Sting, a Swedish startup accelerator/investor network.

Short descriptiontext

CyberGene AB is a Swedish molecular diagnostics company (founded 1995, Solna) that developed and sold proprietary diagnostic products for aneuploidy testing and male infertility testing, serving healthcare providers and diagnostic laboratories. Acquired by Devyser Diagnostics AB in April 2026 for ~SEK 12.2 million.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
molecular diagnostics products, aneuploidy testing kits, male infertility diagnostics, biotech medtech products, reproductive health diagnostics
Industry3 codes
PRIMARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles2 records
Cost components4 values
Supply Chain, Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CyberGene is a Swedish molecular diagnostics company that develops and markets diagnostic testing products in two areas: aneuploidy testing (detecting chromosomal abnormalities in prenatal and reproductive health contexts) and male infertility testing. The products are sold to medical diagnostic laboratories and healthcare providers, supporting reproductive-health and genetic-screening workflows.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CyberGene is a Swedish molecular diagnostics company that develops and markets products in the fields of aneuploidy and male infertility testing. The company operated as a subsidiary within the Level Bio AB group until its acquisition by Devyser Diagnostics AB in April 2026. CyberGene's portfolio consists of two core product categories: aneuploidy testing products and male infertility testing products, both serving the molecular diagnostics market.

Product and service2 records
1Aneuploidy Testing Products
CategoryMolecular Diagnostics
Description

Diagnostic products used to detect chromosomal abnormalities (aneuploidy) in prenatal and reproductive health contexts, sold to medical diagnostic laboratories and healthcare providers.

2Male Infertility Testing Products
CategoryMolecular Diagnostics
Description

Diagnostic products for male infertility testing, supporting reproductive health diagnostics for clinical laboratories and healthcare providers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Devyser acquired 100% of CyberGene shares from Level Bio AB for approximately SEK 12.2 million through a directed issue of new shares. The acquisition was completed on April 1, 2026, after receiving regulatory clearance from the Inspectorate of Strategic Products. This acquisition strengthens Devyser's product portfolio in aneuploidy and male infertility testing.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical diagnostics and life science research company with products in molecular testing and quality controls; comparable to CyberGene in providing laboratory-grade diagnostic products for genetic testing laboratories.

TypeDirect peer
Description

Swedish-listed company providing products and services for assisted reproductive technology (ART), including IVF consumables and genetic testing solutions; directly comparable to CyberGene in serving the reproductive-health diagnostics customer base.

TypeBroad incumbent
Description

Major life sciences tools and diagnostics provider offering qPCR and NGS-based assays used in aneuploidy screening and infertility testing; competes broadly in molecular diagnostics workflows relevant to CyberGene.

TypeBroad incumbent
Description

Global molecular diagnostics and sample technologies company offering genetic testing kits and assays across reproductive health and hereditary disease; overlaps with CyberGene's molecular IVD product category.

TypeBroad incumbent
Description

Diversified diagnostics and women's health company with a strong portfolio in cytogenetic and prenatal screening assays; directly competes with CyberGene in the aneuploidy/PGT testing category through its diagnostic solutions business.

TypeBroad incumbent
Description

Provides reproductive health and genetic testing products, including aneuploidy screening reagents, serving clinical and reference laboratories; comparable to CyberGene in molecular diagnostics for reproductive genetics.

TypeBroad incumbent
Description

Global provider of medical devices and genetic testing services focused on women's health, fertility, and reproductive diagnostics; overlaps with CyberGene's aneuploidy and infertility testing offerings within a much broader portfolio.

TypeBroad incumbent
Description

Dominant NGS platform provider whose technology underpins many aneuploidy and reproductive-genetics tests globally; an enabling incumbent whose sequencing technology competes with or enables products like CyberGene's.

9Yourgene Health (a Sonic Genetics brand)
TypeEmerging player
Description

UK-based molecular diagnostics company specializing in reproductive health and aneuploidy screening (notably NIPT); a more focused emerging competitor directly comparable to CyberGene in the aneuploidy testing niche.

TypeDirect peer
Description

Swedish molecular diagnostics company specializing in hereditary disease and oncology testing kits; acquired CyberGene in April 2026, directly integrating its aneuploidy and male infertility product lines into Devyser's diagnostic test portfolio.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CyberGene

Molecular Diagnosticscybergene.com

CyberGene AB is a Swedish molecular diagnostics company (founded 1995, Solna) that developed and sold proprietary diagnostic products for aneuploidy testing and male infertility testing, serving healthcare providers and diagnostic laboratories. Acquired by Devyser Diagnostics AB in April 2026 for ~SEK 12.2 million.

What CyberGene does

CyberGene AB is a Swedish molecular diagnostics company founded in 1995 and headquartered in Solna, Sweden. The company developed and marketed diagnostic products in two specialized clinical areas: aneuploidy testing (chromosomal abnormality detection used in prenatal and reproductive health contexts) and male infertility testing. Its products were positioned to medical diagnostic laboratories and healthcare providers requiring molecular diagnostics solutions in reproductive genetics. The company operated with a small team of 1-10 employees and was a wholly-owned subsidiary of the Level Bio AB Group for an extended period prior to its divestiture.

The company's business model centered on the development, manufacture, and sale of proprietary diagnostic kits/tests in niche reproductive health segments. Pricing was not publicly disclosed, and no direct revenue figure was reported; however, the 2026 transaction terms imply 2025 net revenue of approximately SEK 7.2 million (~USD 0.83 million), calculated from the disclosed 1.7x revenue acquisition multiple. CyberGene served a vertical customer base of healthcare providers and diagnostic laboratories, with a focused, use-case-driven segmentation approach.

In February 2026, Devyser Diagnostics AB announced an agreement to acquire 100% of CyberGene shares from Level Bio AB for approximately SEK 12.2 million (~USD 1.4 million) via a directed new share issue. The transaction received regulatory clearance from the Swedish Inspectorate of Strategic Products under the Foreign Direct Investments Act and closed on April 1, 2026. Post-acquisition, CyberGene's products are being integrated into Devyser's diagnostic portfolio, with the deal expected to strengthen Devyser's aneuploidy and male infertility offering and have a positive impact on gross profit and EBIT. CyberGene's prior funding history includes an early-stage investment from Sting, a Swedish startup accelerator/investor network.

CyberGene firmographics

Firmographics
Name
CyberGene
Legal name
CyberGene AB
Website
https://cybergene.com
Company type
Private
Founded year
1998
Operating status
Acquired
Headcount range
1–10 employees
Short description
CyberGene AB is a Swedish molecular diagnostics company (founded 1995, Solna) that developed and sold proprietary diagnostic products for aneuploidy testing and male infertility testing, serving healthcare providers and diagnostic laboratories. Acquired by Devyser Diagnostics AB in April 2026 for ~SEK 12.2 million.
Ownership category
akta.pro rank

CyberGene industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Molecular diagnostics products
  • Aneuploidy testing kits
  • Male infertility diagnostics
  • Biotech medtech products
  • Reproductive health diagnostics

Where CyberGene is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Markets served

CyberGene business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations

CyberGene product offering

Product offering

Core offering

CyberGene is a Swedish molecular diagnostics company that develops and markets diagnostic testing products in two areas: aneuploidy testing (detecting chromosomal abnormalities in prenatal and reproductive health contexts) and male infertility testing. The products are sold to medical diagnostic laboratories and healthcare providers, supporting reproductive-health and genetic-screening workflows.

Product overview

CyberGene is a Swedish molecular diagnostics company that develops and markets products in the fields of aneuploidy and male infertility testing. The company operated as a subsidiary within the Level Bio AB group until its acquisition by Devyser Diagnostics AB in April 2026. CyberGene's portfolio consists of two core product categories: aneuploidy testing products and male infertility testing products, both serving the molecular diagnostics market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Aneuploidy Testing Products Diagnostic products used to detect chromosomal abnormalities (aneuploidy) in prenatal and reproductive health contexts, sold to medical diagnostic laboratories and healthcare providers.
  • Male Infertility Testing Products Diagnostic products for male infertility testing, supporting reproductive health diagnostics for clinical laboratories and healthcare providers.

Companies that use CyberGene

Customer profile

Segments1 record

Ideal customer profiles1 record

CyberGene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

CyberGene partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Devyser Diagnostics ABcoreStrategic or Co-development Partner · 1 April 2026Devyser acquired 100% of CyberGene shares from Level Bio AB for approximately SEK 12.2 million through a directed issue of new shares. The acquisition was completed on April 1, 2026, after receiving regulatory clearance from the Inspectorate of Strategic Products. This acquisition strengthens Devyser's product portfolio in aneuploidy and male infertility testing.

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

CyberGene competitors and assessment

Company assessment

Broad incumbents

  • Bio-Rad Laboratories, Inc. Clinical diagnostics and life science research company with products in molecular testing and quality controls; comparable to CyberGene in providing laboratory-grade diagnostic products for genetic testing laboratories.
  • Thermo Fisher Scientific Inc. Major life sciences tools and diagnostics provider offering qPCR and NGS-based assays used in aneuploidy screening and infertility testing; competes broadly in molecular diagnostics workflows relevant to CyberGene.
  • QIAGEN N.V. Global molecular diagnostics and sample technologies company offering genetic testing kits and assays across reproductive health and hereditary disease; overlaps with CyberGene's molecular IVD product category.
  • Hologic, Inc. Diversified diagnostics and women's health company with a strong portfolio in cytogenetic and prenatal screening assays; directly competes with CyberGene in the aneuploidy/PGT testing category through its diagnostic solutions business.
  • Revvity (formerly PerkinElmer Life Sciences): Provides reproductive health and genetic testing products, including aneuploidy screening reagents, serving clinical and reference laboratories; comparable to CyberGene in molecular diagnostics for reproductive genetics.
  • CooperSurgical: Global provider of medical devices and genetic testing services focused on women's health, fertility, and reproductive diagnostics; overlaps with CyberGene's aneuploidy and infertility testing offerings within a much broader portfolio.
  • Illumina, Inc. Dominant NGS platform provider whose technology underpins many aneuploidy and reproductive-genetics tests globally; an enabling incumbent whose sequencing technology competes with or enables products like CyberGene's.

Direct peers

  • Vitrolife AB: Swedish-listed company providing products and services for assisted reproductive technology (ART), including IVF consumables and genetic testing solutions; directly comparable to CyberGene in serving the reproductive-health diagnostics customer base.
  • Devyser Diagnostics AB: Swedish molecular diagnostics company specializing in hereditary disease and oncology testing kits; acquired CyberGene in April 2026, directly integrating its aneuploidy and male infertility product lines into Devyser's diagnostic test portfolio.

Emerging players

  • Yourgene Health (a Sonic Genetics brand): UK-based molecular diagnostics company specializing in reproductive health and aneuploidy screening (notably NIPT); a more focused emerging competitor directly comparable to CyberGene in the aneuploidy testing niche.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

CyberGene social profiles

Digital presence

CyberGene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CyberGene leadership team

Management profile

Number of profiles

CyberGene funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CyberGene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CyberGene

What does CyberGene do?

CyberGene is a Swedish molecular diagnostics company that develops and markets diagnostic testing products in two areas: aneuploidy testing (detecting chromosomal abnormalities in prenatal and reproductive health contexts) and male infertility testing. The products are sold to medical diagnostic laboratories and healthcare providers, supporting reproductive-health and genetic-screening workflows.

Is CyberGene a public or private company?

CyberGene is a private company. It is classified as corporate owned and is currently acquired.

When was CyberGene founded?

CyberGene was founded in 1998. It employs 1 to 10 people.

Where is CyberGene based?

CyberGene is headquartered in Stockholm, Sweden, in the Europe region.

Who are CyberGene's main competitors?

Broad incumbents on record are Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Hologic, Inc., Revvity (formerly PerkinElmer Life Sciences), CooperSurgical and Illumina, Inc.. Direct peers are Vitrolife AB and Devyser Diagnostics AB. Yourgene Health (a Sonic Genetics brand) is listed as an emerging player.

Does CyberGene have an API?

No public API is recorded for CyberGene.

What industry is CyberGene in?

CyberGene's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LevelbioDevyser förvärvar Level Bios dotterbolag CyberGeneLevel Bio has agreed to sell its subsidiary CyberGene to Devyser for approximately 12.2 MSEK, with the purchase price set at 1.7x CyberGene's 2025 net revenue. The transaction will be settled through Devyser issuing shares that will be exchanged for the receivable from the buyer. The divestment is intended to strengthen Level Bio's balance sheet and enable greater focus on its core subsidiary Techtum Lab's Nordic expansion as a distribution company. The deal is subject to ISP regulatory approval under FDI law and expected to close on April 1, 2026.MarketScreenerDevyser Acquires Cybergene for 12 Million KronorDiagnostics company Devyser has entered into an agreement to acquire all shares in Swedish firm Cybergene, which develops and markets products in the fields of aneuploidy and male infertility. The purchase price amounts to approximately 12.2 million kronor and will be paid through a directed new share issue to the seller, Level Bio. The acquisition is expected to strengthen Devyser's offering in the aneuploidy segment and have a positive impact on gross profit and EBIT, with completion planned no later than April 1, 2026, pending regulatory approvals.GenomeWebDevyser Diagnostics to Acquire CyberGene; Reports Q4, Full-Year ProfitSwedish molecular diagnostics company Devyser Diagnostics has agreed to acquire CyberGene, a diagnostics firm specializing in aneuploidy and male infertility testing, for SEK12.2 million ($1.4 million) in newly issued Devyser shares. The company reported its first positive full-year operating result of SEK 10.1 million for 2025, with Q4 operating profit of SEK 18.0 million and full-year sales rising 15 percent to SEK 250.5 million. The acquisition is expected to close by April 1, subject to regulatory approvals under the Swedish Screening of Foreign Direct Investments Act.DevyserDevyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy marketDevyser Diagnostics AB has entered into an agreement to acquire 100% of the shares in Cybergene AB, a Swedish company within the Level Bio AB group, for approximately SEK 12.2 million through a directed issue of new shares. The acquisition is expected to strengthen Devyser's product portfolio in aneuploidy and male infertility while improving gross profit, gross margin, and EBIT. The transaction is conditional upon regulatory clearance from the Inspectorate of Strategic Products and is expected to close on April 1, 2026.